Here we presented a crystal structure of hBLT1 co-crystallized with antagonist MK-D-046, which was part of a panel of BLT1 antagonists developed for the treatment of T2D and other conditions that may be responsive to BLT1 antagonism24. This evidence concerns the gene LTB4R and type 2 diabetes mellitus.